Most Indian women can name the warning signs of breast cancer, but ask about ovarian cancer and you'll usually get a blank look. That silence is exactly what makes it so dangerous. Often called the "silent killer", ovarian cancer hides behind everyday complaints — bloating, a feeling of fullness, mild tummy pain — that most women blame on gas, periods, or a heavy meal. By the time it is caught, it has frequently spread. India today reports among the highest absolute numbers of ovarian cancer cases in the world, and this guide will help you recognise the signs early, understand the tests, and know your options.
Ovarian Cancer in India: Why It Deserves Your Attention
Ovarian cancer is the third most common cancer among Indian women, after breast and cervical cancer. According to the ICMR's National Cancer Registry Programme and GLOBOCAN data, India records tens of thousands of new cases every year, and the country sits among the top nations worldwide for total case numbers.
The truly worrying part is when it is found. Globally, only about 1 in 5 ovarian cancers are caught at an early, localised stage. In India, the picture is worse — in hospital studies, roughly 60% of women present at FIGO Stage III or IV, when the cancer has already spread across the abdomen or beyond. That single fact explains India's survival gap.
The contrast is stark. When ovarian cancer is diagnosed at Stage I, the 5-year survival rate is around 90% or higher. Once it reaches Stage III or IV, five-year survival can fall below 30%. The cancer itself is not always more aggressive in India — the problem is delay, low awareness, and the lack of any reliable population-wide screening test.
There is no equivalent of the Pap smear or mammogram for ovaries. That makes symptom awareness the single most powerful tool an Indian woman has.
Recognising the Warning Signs You Shouldn't Dismiss
The reason ovarian cancer earns its "silent" reputation is that early symptoms are vague and easy to brush aside. But research shows these symptoms are usually present — women just don't connect them to anything serious. See a doctor if any of these are new, persistent (lasting more than 2–3 weeks), and happening more than 12 times a month:
- Persistent bloating or a visibly swollen abdomen that doesn't settle
- Feeling full quickly while eating, or loss of appetite
- Pelvic or lower abdominal pain that doesn't follow your monthly cycle
- Needing to urinate urgently or more often than usual
- Unexplained fatigue, indigestion, or back pain
- Changes in bowel habits, including new constipation
- Unexplained weight loss or, paradoxically, abdominal weight gain
- Bleeding after menopause or irregular bleeding
In Indian hospital studies, abdominal distension and pain were reported by over 90% of patients — yet many had been treated for "gas", acidity, or a urinary infection for months before the real diagnosis. The lesson is simple: if your bloating or tummy discomfort is new and refuses to go away, do not keep buying antacids. Ask your doctor specifically about your ovaries.
Who Is at Higher Risk?
Any woman with ovaries can develop this cancer, but certain factors raise the odds. Knowing yours helps you and your doctor decide how vigilant to be.
Age and Reproductive History
- Age: Risk rises after 40 and peaks in the 50s and 60s, around and after menopause.
- Never having children (nulliparity) or having a first child late.
- Infertility or never having used hormonal contraception.
- Early menstruation (before 12) or late menopause (after 52) — more lifetime ovulation cycles mean more risk.
- Endometriosis is linked to certain types of ovarian cancer.
Family History and Genetics
This is the most important risk factor to act on. Up to 15–20% of ovarian cancers are hereditary, most often caused by inherited BRCA1 and BRCA2 gene mutations — the same genes linked to hereditary breast cancer. A woman who inherits a BRCA1 mutation can carry a lifetime ovarian cancer risk of up to 40%.
If your mother, sister, or daughter has had ovarian or breast cancer — especially at a young age — you should discuss genetic counselling and BRCA testing with a doctor. Indian studies suggest our population may carry some distinct mutation patterns, so testing matters here too. If you carry a high-risk mutation, your doctor can plan closer monitoring or risk-reducing options.
Lifestyle Factors
- Obesity, increasingly common in urban India, is associated with higher risk.
- Long-term hormone replacement therapy after menopause.
- Protective factors, on the other hand, include pregnancy, breastfeeding, and several years of oral contraceptive pill use, all of which reduce the number of lifetime ovulations.
If you are tracking long-term health risks across your family, keeping every relative's cancer history and reports in one place using a family sharing feature makes it far easier for a doctor to spot a hereditary pattern.
The Tests: CA-125, Ultrasound and Beyond
Because there is no single screening test, doctors use a combination of investigations when ovarian cancer is suspected.
CA-125 Blood Test
CA-125 is a protein that is often raised in ovarian cancer. It is a useful tumour marker, but it has real limitations every woman should understand:
- It is normal in up to half of early-stage ovarian cancers, so a normal result does not rule cancer out.
- It can be falsely high in many benign conditions common in Indian women — endometriosis, fibroids, pelvic infection, even menstruation and pregnancy.
For this reason, CA-125 is not recommended as a standalone screening test for women without symptoms. It is most valuable for monitoring a confirmed cancer's response to treatment over time. A typical CA-125 test costs around ₹600–₹1,200 at Indian labs such as Dr. Lal PathLabs, SRL, or Thyrocare.
Transvaginal Ultrasound (TVS)
A transvaginal ultrasound lets the doctor see the size and structure of the ovaries and detect cysts or masses. Combined with CA-125 and a pelvic examination, it forms the core of the diagnostic workup. Cost ranges from roughly ₹1,500–₹3,500.
Other Tests
- CT or MRI scans to assess how far the cancer has spread.
- HE4 marker and the ROMA score, which combine markers to estimate risk.
- Biopsy or surgery, which provides the definitive diagnosis and tissue type.
- BRCA and other genetic tests for women with a strong family history.
Whatever the panel, the most useful thing you can do is keep your reports organised and comparable over time. A rising CA-125 across three reports tells a very different story than a single number, which is why women under monitoring benefit from MedicalVault's trend analysis to see the trajectory at a glance rather than hunting through old files.
Understanding the Stages
Ovarian cancer is staged using the FIGO system, from I to IV, based on how far it has spread:
| Stage | What it means | Typical 5-year survival |
|---|---|---|
| Stage I | Confined to one or both ovaries | ~90% |
| Stage II | Spread within the pelvis (uterus, tubes) | ~70% |
| Stage III | Spread to the abdominal lining or lymph nodes | ~39% |
| Stage IV | Spread to distant organs (liver, lungs) | ~20% |
These numbers are averages and depend heavily on the cancer type, the success of surgery, and overall health. They are not a prediction for any one person — many women live well beyond them. But they make the case for early action impossible to ignore: catching the disease at Stage I instead of Stage III can more than double the odds of long-term survival.
Treatment Options in India
Ovarian cancer treatment in India is delivered by gynae-oncology teams at major centres such as Tata Memorial (Mumbai), AIIMS, Adyar Cancer Institute (Chennai), and large private hospital networks. The standard approach combines two pillars.
Surgery
The goal is optimal debulking surgery — removing as much of the tumour as possible, often including the ovaries, fallopian tubes, uterus, and affected nearby tissue. How completely the surgeon can remove the disease is one of the strongest predictors of outcome.
Chemotherapy
Most women receive platinum-based chemotherapy (carboplatin combined with paclitaxel), given before or after surgery. Newer treatments have genuinely changed the outlook for advanced and recurrent disease:
- PARP inhibitors such as olaparib, especially effective in BRCA-positive women, are now available in India and have been studied in Indian patients.
- Bevacizumab, a targeted anti-angiogenesis drug.
What It Costs
Ovarian cancer treatment in India typically ranges from ₹3.5 lakh to ₹10 lakh or more, depending on stage, surgery complexity, and how many chemotherapy cycles and targeted drugs are needed. Treatment at government and trust hospitals is substantially cheaper, and the Ayushman Bharat PM-JAY scheme covers cancer care for eligible families. Always discuss the full treatment plan, expected costs, and financial support options with your treating team before starting.
What You Can Actually Do
You cannot screen ovarian cancer away the way you can with cervical cancer, but you are not powerless either.
- Know your body's normal. Persistent bloating, early fullness, or pelvic pain that is new and lasts more than two weeks deserves a doctor's visit — not another strip of antacids.
- Map your family history. If breast or ovarian cancer runs in your family, ask about genetic counselling and BRCA testing.
- Don't skip the pelvic exam at your gynaecologist, especially after 40.
- Consider the protective value of breastfeeding and discuss contraception choices with your doctor.
- Keep your reports together. When a doctor can instantly compare your CA-125 and scans over time, decisions get faster and clearer.
If you've recently had tests done, upload your reports to MedicalVault so your CA-125 values, ultrasounds, and scans live in one place — ready to share with any specialist you consult, without digging through a drawer of old envelopes.
Key Takeaways
- Ovarian cancer is the third most common cancer in Indian women and is usually diagnosed late, when survival is far lower.
- There is no reliable screening test for women without symptoms — awareness of persistent bloating, early fullness, and pelvic pain is your best protection.
- CA-125 can be normal in early cancer and high in harmless conditions, so it is used alongside ultrasound and exams, not on its own.
- A strong family history of breast or ovarian cancer warrants genetic counselling and BRCA testing.
- Caught at Stage I, survival exceeds 90%; caught late, it drops sharply — early action saves lives.
- Treatment combines surgery and platinum-based chemotherapy, with PARP inhibitors offering new hope, and PM-JAY helping eligible families with costs.
- Tracking your tumour markers and scans over time with MedicalVault's trend analysis helps you and your doctor act on changes early rather than late.
Ovarian cancer may be quiet, but you don't have to be. If something in your body feels persistently "off", trust it and get it checked. Explore our features page to see how keeping your health records organised can help you and the women you love stay one step ahead. Always consult your doctor or a gynae-oncologist for personalised advice — this article is for awareness, not diagnosis.